| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation JK Litton, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, ... New England Journal of Medicine 379 (8), 753-763, 2018 | 2067 | 2018 |
| PD-L1 expression in triple-negative breast cancer EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ... Cancer immunology research 2 (4), 361-370, 2014 | 1421 | 2014 |
| Breast cancer before age 40 years CK Anders, R Johnson, J Litton, M Phillips, A Bleyer Seminars in oncology 36 (3), 237-249, 2009 | 1034 | 2009 |
| PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression S Jiao, W Xia, H Yamaguchi, Y Wei, MK Chen, JM Hsu, JL Hsu, WH Yu, ... Clinical Cancer Research 23 (14), 3711-3720, 2017 | 931 | 2017 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 837 | 2021 |
| Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology MB Daly, T Pal, MP Berry, SS Buys, P Dickson, SM Domchek, ... Journal of the National Comprehensive Cancer Network 19 (1), 77-102, 2021 | 780 | 2021 |
| Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer AM Gonzalez-Angulo, KM Timms, S Liu, H Chen, JK Litton, J Potter, ... Clinical Cancer Research 17 (5), 1082-1089, 2011 | 748 | 2011 |
| Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 JH Cha, WH Yang, W Xia, Y Wei, LC Chan, SO Lim, CW Li, T Kim, ... Molecular cell 71 (4), 606-620. e7, 2018 | 673 | 2018 |
| Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian J Mersch, MA Jackson, M Park, D Nebgen, SK Peterson, C Singletary, ... Cancer 121 (2), 269-275, 2015 | 616 | 2015 |
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial F André, R O'Regan, M Ozguroglu, M Toi, B Xu, G Jerusalem, N Masuda, ... The lancet oncology 15 (6), 580-591, 2014 | 598 | 2014 |
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller AM Gonzalez-Angulo, JK Litton, KR Broglio, F Meric-Bernstam, R Rakkhit, ... Journal of clinical oncology 27 (34), 5700-5706, 2009 | 578 | 2009 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017 MB Daly, R Pilarski, M Berry, SS Buys, M Farmer, S Friedman, JE Garber, ... Journal of the National Comprehensive Cancer Network 15 (1), 9-20, 2017 | 515 | 2017 |
| Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer S Yennurajalingam, S Frisbee-Hume, JL Palmer, MO Delgado-Guay, ... Journal of Clinical Oncology 31 (25), 3076-3082, 2013 | 418 | 2013 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines MB Daly, R Pilarski, MB Yurgelun, MP Berry, SS Buys, P Dickson, ... Journal of the National Comprehensive Cancer Network 18 (4), 380-391, 2020 | 403 | 2020 |
| Current landscape of immunotherapy in breast cancer: a review S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ... JAMA oncology 5 (8), 1205-1214, 2019 | 366 | 2019 |
| Genetic/familial high-risk assessment: breast and ovarian MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ... Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010 | 360 | 2010 |
| Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab, ... Annals of Oncology 31 (11), 1526-1535, 2020 | 328 | 2020 |
| Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline NM Tung, JC Boughey, LJ Pierce, ME Robson, I Bedrosian, JR Dietz, ... Journal of clinical oncology 38 (18), 2080-2106, 2020 | 307 | 2020 |
| The impact of pregnancy on breast cancer outcomes in women≤ 35 years BM Beadle, WA Woodward, LP Middleton, W Tereffe, EA Strom, JK Litton, ... Cancer 115 (6), 1174-1184, 2009 | 230 | 2009 |
| Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update HJ Burstein, MR Somerfield, DL Barton, A Dorris, LJ Fallowfield, D Jain, ... Journal of clinical oncology 39 (35), 3959-3977, 2021 | 228 | 2021 |
